Product
NT-112
Aliases
NT-112: Autologous, engineered T Cells targeting KRAS G12D
1 clinical trial
7 indications
Indication
Lung CancerIndication
Colorectal cancerIndication
Pancreatic Ductal AdenocarcinomaIndication
Endometrial CancerIndication
Solid TumorIndication
AdultIndication
KRAS G12DClinical trial
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D MutationStatus: Recruiting, Estimated PCD: 2025-08-30